Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Amelia M. Jernigan is active.

Publication


Featured researches published by Amelia M. Jernigan.


International Journal of Gynecology & Obstetrics | 2014

A randomized trial of chewing gum to prevent postoperative ileus after laparotomy for benign gynecologic surgery

Amelia M. Jernigan; Chi Chiung Grace Chen; Catherine Sewell

To assess whether chewing gum prevents postoperative ileus after laparotomy for benign gynecologic surgery.


International Journal of Gynecological Cancer | 2015

Lifestyle and weight management counseling in uterine cancer survivors: A study of the uterine cancer action network

Jill H. Tseng; Kara Long Roche; Amelia M. Jernigan; Ritu Salani; Robert E. Bristow; Amanda Nickles Fader

Objective The purpose of this study was to examine the experiences, attitudes, and preferences of uterine cancer survivors with regard to weight and lifestyle counseling. Materials and Methods Members of the US Uterine Cancer Action Network of the Foundation for Women’s Cancer were invited to complete a 45-item, Web-based survey. Standard descriptive statistical methods and χ2 tests were used to analyze responses. Results One hundred eighty (28.3%) uterine cancer survivors completed the survey. Median age was 58 years, 85% were white, and median survivorship period was 4.4 years. Most had stage I–II disease (69%) and were overweight or obese (65%). Eighty-nine percent of respondents received care by a gynecologic oncologist. Increased respondent body mass index was associated with decreased exercise frequency (P = 0.016). Only 50% of respondents underwent any weight/lifestyle counseling, with those living in the West and Southwest reporting the highest rates (70.8% and 69.2%, P = 0.011). Most who received counseling felt that discussions were motivating, performed in a sensitive manner, and did not undermine the patient–physician relationship. Specific recommendations were rarely offered; there were no reported referrals to weight loss programs or bariatric specialists, and few (6%) reported referrals to nutritionists. Respondents (85%) preferred their gynecologic oncologist address weight using direct, face-to-face counseling with specific recommendations regarding interventions and referral to specialists. Finally, self-reported overweight respondents experienced greater success with weight loss compared to those reporting obesity or morbid obesity (30.8% vs 15.8% vs 12.5%, P = 0.011). Conclusions Uterine cancer survivors reported high obesity, low activity rates, and a desire for substantive weight loss counseling from their gynecologic oncologists. Respondents suggested that current counseling practices are inadequate and incongruent with their needs. Further research to define optimal timing, interventional strategies, and specific recommendations for successful lifestyle changes in this population is warranted.


Obstetrics and Gynecology International | 2013

Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival.

Amelia M. Jernigan; Amanda Nickles Fader; Benjamin Nutter; Peter G. Rose; Jill H. Tseng; Pedro F. Escobar

Objective. To define survival patterns of women with ovarian carcinosarcoma based on patient, tumor, and treatment characteristics. Methods/Materials. A single-institution, retrospective analysis of women diagnosed with ovarian carcinosarcoma from February 1993 to May 2009 was performed. Survival was analyzed with Cox proportional hazards ratios and Kaplan Meier tests. Results. Forty-seven cases of primary ovarian carcinosarcoma were identified. Age conveyed an HR 3.28 (95% CI 1.51–7.11, P = 0.003) for death. Compared to Stages I-II, Stage III carried an HR for death of 4.75 (95% CI 1.16–19.4, P = 0.03) and Stage IV disease an HR of 9.13 (95% CI 1.76–47.45, P = 0.009). Compared to those with microscopic residual, women with >1 cm diameter of residual disease after primary cytoreductive surgery had an HR for death of 4.71 (95% CI 1.84–12.09, P = 0.001). At analysis, 59.1% of those who received platinum-based chemotherapy were alive, compared to 23.1% of those who received nonplatinum-based chemotherapy (P = 0.08). Conclusions. Age, stage, and cytoreduction to no gross residual disease are associated with improved survival in women with ovarian carcinosarcoma. Complete surgical cytoreduction should be the goal of surgical management when possible, but the ideal adjuvant treatment regimen remains unclear.


Journal of Gynecologic Oncology | 2015

Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion

Haider Mahdi; Amelia M. Jernigan; Benjamin Nutter; C.M. Michener; Peter G. Rose

Objective To investigate the rate, predictors of lymph node metastasis (LNM) and pattern of recurrence in clinically early stage endometrial cancer (EC) with positive lymphovascular space invasion (LVSI). Methods Women with clinically early stage EC and positive LVSI 2005 to 2012 were identified. Kaplan-Meier curves and logistic regression models were used. Results One hundred forty-eight women were identified. Of them, 25.7% had LNM (21.7% pelvic LNM, 18.5% para-aortic LNM). Among patients with LNM who had both pelvic and para-aortic lymphadenectomy, isolated pelvic, para-aortic and both LNM were noted in 51.4%, 17.1%, and 31.4% respectively. Age and depth of myometrial invasion were significant predictors of LNM in LVSI positive EC. Node positive patients had high recurrence rate (47% vs. 11.8%, p<0.05) especially distant (60.9% vs. 7.9%, p<0.001) and para-aortic (13.2% vs. 1.8%, p=0.017) recurrences compared to node negative EC. LNM was associated with lower progression-free survival (p=0.002) but not overall survival (p=0.73). Conclusion EC with positive LVSI is associated with high risk of LNM. LNM is associated with high recurrence rate especially distant and para-aortic recurrences. Adjuvant treatments should target prevention of recurrences in these areas.


International Journal of Gynecological Cancer | 2014

The importance of social support for women with elevated anxiety undergoing care for gynecologic malignancies.

Mary Kimmel; Melissa Gerardi Fairbairn; Robert L. Giuntoli; Amelia M. Jernigan; Anna Belozer; Jennifer L. Payne; Karen Swartz; Teresa P. Díaz-Montes

Objectives The aim of this study was to screen for depression and anxiety and to assess well-being among women diagnosed with gynecologic malignancies, identify factors associated with elevated depressive or anxiety symptoms, and further characterize the needs of those with elevated anxiety or depressive symptoms. Methods/Materials Women presenting for gynecologic cancer at an academic center during the course of 10 months were offered screening for depressive and anxiety symptoms. Patients were screened with the Primary Care Evaluation of Mental Disorders’ Patient Health Questionnaire-9 and the Generalized Anxiety Disorder-7. The Functional Assessment of Cancer Therapy-General assessed well-being. Demographics, psychiatric history, and components about the cancer and treatment were collected. Those who screened positive with scores of 10 or higher on the Patient Health Questionnaire-9 or the Generalized Anxiety Disorder-7 were offered a meeting with the study psychiatrist for further evaluation both with the Structured Clinical Interview for Diagnosis as well as with an interview to discuss their experiences and to assess their desired needs. Results When family and social well-being was added to the logistic regression model, higher family and social well-being was the strongest factor associated with lower amounts of anxiety (odds ratio, 0.10; P = 0.001 for a cutoff of 10; odds ratio, 0.21; P = 0.012 for a cutoff of 8). Less than 30% who screened positive met with the study psychiatrist and were not receiving optimal treatment. Conclusions Given that low family and social well-being and elevated anxiety symptoms were so highly correlated, those with anxiety symptoms would most benefit from social interventions. However, this study also found that patients with elevated depressive or anxiety symptoms were difficult to engage with a psychiatric provider. We need partnership between psychiatry and gynecology oncology to identify those with elevated depressive and anxiety symptoms and develop better ways to provide psychosocial supports.


American Journal of Obstetrics and Gynecology | 2013

Obesity management in gynecologic cancer survivors: Provider practices and attitudes

Amelia M. Jernigan; Andrew J. Satin; Amanda Nickles Fader


Women's Health | 2012

Minimally invasive surgery in gynecologic oncology: a review of modalities and the literature

Amelia M. Jernigan; Melinda Auer; Amanda Nickles Fader; Pedro F. Escobar


Gynecologic Oncology | 2015

Endometrial cancer survivor perspectives on weight loss and lifestyle modifications: a Uterine Cancer Action Network study

Jill H. Tseng; K.C. Long; Amelia M. Jernigan; Ritu Salani; Robert E. Bristow; A. Nickles Fader


Gynecologic Oncology | 2013

Pilot study evaluating the integration of psychological assessment among women undergoing care for gynecologic malignancies

Teresa P. Díaz-Montes; M. Gerardi Fairbairn; Amelia M. Jernigan; A. Belozer; Robert L. Giuntoli; Mary Kimmel


Gynecologic Oncology | 2012

Ovarian sarcoma: Clinicopathological characteristics and prognostic factors

Amelia M. Jernigan; B. Nutter; P. Rose; Amanda Nickles Fader; P. Escobar

Collaboration


Dive into the Amelia M. Jernigan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jill H. Tseng

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Mary Kimmel

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge